Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis

Liver fibrosis is characterized by excessive deposition of extracellular matrix due to chronic inflammation of the liver. Hepatic stellate cells (HSCs) become activated and produce increased amounts of extracellular matrix. Loss of HIF-prolyl-hydroxylase 1 (PHD1) attenuates HSC activation and fibrot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tuffs, Christopher (VerfasserIn) , Dupovac, Mareen (VerfasserIn) , Richter, Katrin (VerfasserIn) , Holten, Sophia (VerfasserIn) , Schaschinger, Thomas (VerfasserIn) , Marg, Oliver (VerfasserIn) , Poljo, Adisa (VerfasserIn) , Tasdemir, Ayse nur (VerfasserIn) , Harnoß, Jonathan M. (VerfasserIn) , Billeter, Adrian (VerfasserIn) , Schneider, Martin (VerfasserIn) , Strowitzki, Moritz (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2025
In: The American journal of pathology
Year: 2025, Jahrgang: 195, Heft: 3, Pages: 480-493
ISSN:1525-2191
DOI:10.1016/j.ajpath.2024.10.018
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ajpath.2024.10.018
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0002944024004115
Volltext
Verfasserangaben:Christopher Tuffs, Mareen Dupovac, Katrin Richter, Sophia Holten, Thomas Schaschinger, Oliver Marg, Adisa Poljo, Ayse nur Tasdemir, Jonathan M. Harnoss, Adrian Billeter, Martin Schneider, and Moritz J. Strowitzki

MARC

LEADER 00000caa a2200000 c 4500
001 1931592470
003 DE-627
005 20250913141739.0
007 cr uuu---uuuuu
008 250723s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ajpath.2024.10.018  |2 doi 
035 |a (DE-627)1931592470 
035 |a (DE-599)KXP1931592470 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Tuffs, Christopher  |d 1994-  |e VerfasserIn  |0 (DE-588)1261772067  |0 (DE-627)1809061830  |4 aut 
245 1 0 |a Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis  |c Christopher Tuffs, Mareen Dupovac, Katrin Richter, Sophia Holten, Thomas Schaschinger, Oliver Marg, Adisa Poljo, Ayse nur Tasdemir, Jonathan M. Harnoss, Adrian Billeter, Martin Schneider, and Moritz J. Strowitzki 
264 1 |c March 2025 
300 |b Illustrationen 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar 19 November 2024, Version des Artikels 21 February 2025 
500 |a Gesehen am 23.07.2025 
520 |a Liver fibrosis is characterized by excessive deposition of extracellular matrix due to chronic inflammation of the liver. Hepatic stellate cells (HSCs) become activated and produce increased amounts of extracellular matrix. Loss of HIF-prolyl-hydroxylase 1 (PHD1) attenuates HSC activation and fibrotic tissue remodeling in a murine model of biliary liver fibrosis. Herein, the protective effect of PHD1 deficiency (PHD1−/−) in an additional (toxic) model of liver fibrosis was validated and the effect of dimethyloxalylglycine (DMOG), a pan-HIF-prolyl-hydroxylase inhibitor, on the development of liver fibrosis, was evaluated. Liver fibrosis was induced utilizing carbon tetrachloride in wild-type (WT) and PHD1−/− mice treated with either vehicle or DMOG. To assess fibrosis development, expression of profibrotic genes in the livers was analyzed by Sirius red staining. When compared with WT mice, PHD1−/− mice developed less-severe liver fibrosis. DMOG treatment did not prevent this liver fibrosis. PHD1−/− mice had fewer α-SMA+ cells and less macrophage infiltration compared with WT mice. Expression of profibrogenic and proinflammatory genes was reduced in livers from carbon tetrachloride-exposed PHD1−/− mice. In vitro analyses of PHD1-deficient human HSCs revealed attenuated mRNA levels of profibrotic genes, as well as impaired migration and invasion. Although PHD1 deficiency attenuated activation of HSCs, pharmacologic PHD inhibition did not ameliorate fibrosis development. These data indicate that selective PHD1 inhibitors could prove effective in preventing and treating liver fibrosis. 
700 1 |a Dupovac, Mareen  |e VerfasserIn  |0 (DE-588)1276105827  |0 (DE-627)1827926848  |4 aut 
700 1 |a Richter, Katrin  |e VerfasserIn  |4 aut 
700 1 |a Holten, Sophia  |e VerfasserIn  |4 aut 
700 1 |a Schaschinger, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Marg, Oliver  |e VerfasserIn  |4 aut 
700 1 |a Poljo, Adisa  |e VerfasserIn  |4 aut 
700 1 |a Tasdemir, Ayse nur  |e VerfasserIn  |4 aut 
700 1 |a Harnoß, Jonathan M.  |d 1986-  |e VerfasserIn  |0 (DE-588)1065010915  |0 (DE-627)827807511  |0 (DE-576)424699524  |4 aut 
700 1 |a Billeter, Adrian  |d 1984-  |e VerfasserIn  |0 (DE-588)1071497499  |0 (DE-627)825950732  |0 (DE-576)433113804  |4 aut 
700 1 |a Schneider, Martin  |e VerfasserIn  |4 aut 
700 1 |a Strowitzki, Moritz  |d 1987-  |e VerfasserIn  |0 (DE-588)1071578561  |0 (DE-627)82605532X  |0 (DE-576)433164638  |4 aut 
773 0 8 |i Enthalten in  |t The American journal of pathology  |d New York [u.a.] : Elsevier, 1925  |g 195(2025), 3 vom: März, Seite 480-493  |h Online-Ressource  |w (DE-627)271352906  |w (DE-600)1480207-7  |w (DE-576)078591732  |x 1525-2191  |7 nnas  |a Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis 
773 1 8 |g volume:195  |g year:2025  |g number:3  |g month:03  |g pages:480-493  |g extent:14  |a Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis 
856 4 0 |u https://doi.org/10.1016/j.ajpath.2024.10.018  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0002944024004115  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250723 
993 |a Article 
994 |a 2025 
998 |g 1071578561  |a Strowitzki, Moritz  |m 1071578561:Strowitzki, Moritz  |d 50000  |e 50000PS1071578561  |k 0/50000/  |p 12  |y j 
998 |g 1071497499  |a Billeter, Adrian  |m 1071497499:Billeter, Adrian  |d 50000  |e 50000PB1071497499  |k 0/50000/  |p 10 
998 |g 1065010915  |a Harnoß, Jonathan M.  |m 1065010915:Harnoß, Jonathan M.  |d 50000  |e 50000PH1065010915  |k 0/50000/  |p 9 
998 |g 1276105827  |a Dupovac, Mareen  |m 1276105827:Dupovac, Mareen  |d 50000  |e 50000PD1276105827  |k 0/50000/  |p 2 
999 |a KXP-PPN1931592470  |e 4749091561 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis","title_sort":"Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosis"}],"language":["eng"],"person":[{"family":"Tuffs","display":"Tuffs, Christopher","given":"Christopher","role":"aut"},{"role":"aut","given":"Mareen","display":"Dupovac, Mareen","family":"Dupovac"},{"family":"Richter","display":"Richter, Katrin","given":"Katrin","role":"aut"},{"family":"Holten","display":"Holten, Sophia","given":"Sophia","role":"aut"},{"display":"Schaschinger, Thomas","role":"aut","given":"Thomas","family":"Schaschinger"},{"display":"Marg, Oliver","role":"aut","given":"Oliver","family":"Marg"},{"family":"Poljo","display":"Poljo, Adisa","given":"Adisa","role":"aut"},{"family":"Tasdemir","display":"Tasdemir, Ayse nur","given":"Ayse nur","role":"aut"},{"role":"aut","given":"Jonathan M.","display":"Harnoß, Jonathan M.","family":"Harnoß"},{"family":"Billeter","role":"aut","given":"Adrian","display":"Billeter, Adrian"},{"family":"Schneider","given":"Martin","role":"aut","display":"Schneider, Martin"},{"display":"Strowitzki, Moritz","given":"Moritz","role":"aut","family":"Strowitzki"}],"name":{"displayForm":["Christopher Tuffs, Mareen Dupovac, Katrin Richter, Sophia Holten, Thomas Schaschinger, Oliver Marg, Adisa Poljo, Ayse nur Tasdemir, Jonathan M. Harnoss, Adrian Billeter, Martin Schneider, and Moritz J. Strowitzki"]},"id":{"doi":["10.1016/j.ajpath.2024.10.018"],"eki":["1931592470"]},"physDesc":[{"extent":"14 S.","noteIll":"Illustrationen"}],"note":["Online verfügbar 19 November 2024, Version des Artikels 21 February 2025","Gesehen am 23.07.2025"],"relHost":[{"pubHistory":["1.1925 -"],"language":["eng"],"part":{"text":"195(2025), 3 vom: März, Seite 480-493","year":"2025","volume":"195","issue":"3","pages":"480-493","extent":"14"},"title":[{"title":"The American journal of pathology","subtitle":"cellular and molecular biology of disease ; official publication of the American Society for Investigative Pathology","title_sort":"American journal of pathology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"271352906","origin":[{"dateIssuedDisp":"1925-","publisher":"Elsevier ; American Society for Investigative Pathology","dateIssuedKey":"1925","publisherPlace":"New York [u.a.] ; Bethesda, Md."}],"note":["Gesehen am 19.02.2024"],"disp":"Genetic loss of HIF-prolyl-hydroxylase 1, but not pharmacological inhibition, mitigates hepatic fibrosisThe American journal of pathology","id":{"zdb":["1480207-7"],"issn":["1525-2191"],"eki":["271352906"]},"physDesc":[{"extent":"Online-Ressource"}]}],"recId":"1931592470","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"March 2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} 
SRT |a TUFFSCHRISGENETICLOS2025